Key Takeaways for Johnson & Johnson Stock as of August 2026
- YTD Climb: JNJ stock is up 53% over the past year to $268.04.
- Street Split: Twenty-four analysts cover the stock with 11 buys, 5 outperforms, 6 holds, and 1 sell, and the $272.50 mean target sits just 2% above the current price.
- Model Ceiling: TIKR’s mid-case model prices Johnson & Johnson at $279 by 2030, implying just 4% total return and 1% annualized from here.
- Overhangs Cleared: A $5.5 billion talc settlement and FDA approval for the OTTAVA surgical robot removed two long-standing risks this quarter.
Why Johnson & Johnson Stock Is Up 53% After a Year of Raised Guidance
Johnson & Johnson (JNJ) stock has climbed 53% over the past year, closing at $268.04 on August 28 after starting near $175 last September.
The move traces back to a Q2 report on July 15 that beat on both lines, $25.31 billion in sales against a $25.05 billion estimate, and adjusted earnings per share of $2.90 versus $2.85 expected. Johnson & Johnson followed the beat with a guidance raise that keeps the company on pace to cross $100 billion in annual revenue for the first time in its 140-year history.
CFO Joe Wolk framed the increase directly on the Q2 earnings call: “We are pleased to increase our adjusted operational earnings per share range to $11.50 to $11.65, which equates to an increase of $0.18 at the midpoint. This represents year-on-year adjusted operational EPS growth of 7.3%.” That kind of raise, on top of a quarter where the business excluding Stelara grew more than 14%, is what pulled the stock’s re-rating forward.
New drugs did the rest. Tremfya’s sales grew 71% to $2 billion in the quarter, and three launches, Icotyde in psoriasis, Imaavy in the rare blood disorder wAIHA, and Inlexzo in bladder cancer, layered fresh growth onto a base most investors had already modeled. Imaavy picked up expanded FDA approval on August 24, and Icotyde cleared Chinese regulators on August 27.
The stock also stopped paying a legal discount. Johnson & Johnson settled roughly 76,000 talc claims for at least $5.5 billion in July, closing out litigation that had weighed on the shares since 2018. A federal judge added to the clean-up on August 19, ruling that three researchers who published talc research did not defame the company.
A beat-and-raise quarter, three drug approvals inside a single month, and a legal overhang finally settled explain why Johnson & Johnson stock is up 53% in a year. What’s left to answer is whether the Street and the model still see room to run from here.
OTTAVA’s FDA Approval Gives Johnson & Johnson Stock a New Growth Lever
The re-rating got another leg on August 3, when Johnson & Johnson said its OTTAVA robotic surgical system received De Novo authorization from the FDA, its first entry into soft-tissue robotic surgery. Worldwide Chairman of MedTech Tim Schmid told investors on a special call the program carries real financial weight: “we are absolutely adamant that this will be a financially material program for Johnson & Johnson by the end of the decade.” He pointed investors to the company’s Enterprise Business Review on December 8 for detail on placements and targets.
OTTAVA enters a market where fewer than 8% of eligible soft-tissue procedures worldwide are performed robotically today, by management’s own account, against an incumbent that has run largely unchallenged for two decades. Johnson & Johnson also has Monarch, its bronchoscopy robot, expanding this year, giving MedTech two robotic launches to lean on as cardiovascular growth cools.
Analysts Have Chased Johnson & Johnson Stock Higher, Not Ahead of It
Twenty-four analysts cover Johnson & Johnson stock, split into 11 buys, 5 outperforms, 6 holds, and 1 sell as of August 28. That’s the most bullish tilt the table has carried in over a year, up from 7 buys and 13 holds back in June 2025. The mean target sits at $272.50, just 2% above the $268.04 close.
That 2% gap isn’t new. The mean target has tracked within a point or two of the closing price in every quarter since September 2025, moving from $179.64 to $272.50 as the stock itself ran from $179.71 to $268.04 over the same stretch.
Analysts have raised the number in step with the price rather than getting ahead of it, a different posture than the 11% premium the target carried back in June 2025. The ratings shift, more buys, fewer holds, shows conviction building even as the raw upside stays thin, the profile of a stock the Street believes in but no longer treats as cheap.
TIKR Values Johnson & Johnson Stock at $279, a Modest 4% From Here
TIKR’s mid-case model values Johnson & Johnson at $279 by December 2030, implying a 4% total return from the current price of $268, or 1% annualized over 4.3 years.
That return puts Johnson & Johnson stock closer to a bond proxy than a growth compounder over the model’s window, a modest ask for a name that just posted a year of double-digit earnings growth outside Stelara.
The gap between the stock’s 53% run and TIKR’s near-flat forward number comes down to timing. The market has already priced in the guidance raise, the launches, and the litigation settlement that drove Section 1’s move, leaving less room for the model to add on top of a price that has already caught up to the news.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Johnson & Johnson stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
